Ovarian Cancer Clinical Roundup
(Yahoo! Finance) Oct 5, 2020 - First clinical study to combine ZEN-3694 with BMS’s immune checkpoint inhibitors nivolumab and ipilimumab for treatment of ovarian cancer.
(Karolinska Institutet [Sweden]) Sept 25, 2020 - Women receiving fertility-sparing surgery for treatment of borderline ovarian tumours were able to have children, a study from Karolinska Institutet in Sweden published in Fertility & Sterility shows.
(Ann Oncol) - 2020-09-28
(Int J Cancer) - 2020-10-09
(JAMA Oncol) - 2020-10-08
(Br J Cancer) - 2020-09-30
PARP inhibition continues to steal the spotlight in advanced ovarian cancer, even in the absence of pivotal trial data.
Findings presented at the European Society of Medical Oncology (ESMO) Virtual Congress 2020 showed a significant benefit for PARP inhibition earlier in the cancer pathway, offering hope for more long-term survivors, while other treatment paradigms such as immunotherapy failed again to make headway against the disease.